Skip to content
etf.net

SBIO

GradeCNew York Stock Exchange Arca

ALPS Medical Breakthroughs ETF

Themes · ALPS Funds · Inception 2014-12-30 · SEC filings

$59.51−3.84 (−6.06%)

As of Sep 23, 2026, 2:25 PM EDT

Intraday session: down, 59 prints from 63.35 to 59.51. Range 59.44 to 63.19. Use the arrow keys to read each point.$59.00$60.00$61.00$62.00$63.0010 AM12 PM2 PM4 PM
Expense ratio
0.50%
Fund size
$226M
1Y return
+68.8%
Yield · Last 12 months
0.00%
Holdings
103
Volume · 30D
0M sh
NAV per share
$62.38
52W range
low $36.84high $70.85

The ETF.net SBIO Grade

C

48/ 100

Rank 9 of 17 in Biotech & Genomics⁠

Confidence Medium

Six-pillar profile for SBIO. Scores out of 100: Cost 38, Risk 38, Mission not scored, Tradability 57, Holdings 80, Durability 55. Strongest: Holdings (80). Weakest: Risk (38). Based on 5 of 6 pillars.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 48 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    DScore 38
    Category rank12/17 · mid-pack

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    Not scored
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    DScore 38
    Category rank13/17 · bottom quartile

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    BScore 57
    Category rank7/17 · top 41%

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    AScore 80
    Category rank4/17 · top 24%

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    BScore 55
    Category rank9/17 · mid-pack

Graded as of Sep 22, 2026 · Based on 5 of 6 pillars

Our read on SBIO

ETF.net Research

CSBIO goes at biotech through a purpose-built medical breakthroughs index instead of the household benchmarks, spreading roughly 100 drug developers across one basket. A specialist route, priced at the category's middle.

Stated mandate

The fund seeks investment results that generally track, before fees and expenses, the performance of the S-Network Medical Breakthroughs Index (PMBI).

Why people hold it

  1. 01Tracks the S-Network Medical Breakthroughs Index, a dedicated rules-based basket rather than the standard biotech benchmarks most funds in the group follow.
  2. 02Roughly 100 holdings, so no single drug readout carries the whole fund.
  3. 03The 0.50% expense ratio sits right at the median for biotech and genomics funds. No premium charged for the narrower mandate.
  4. 04Trading since 2014, giving it a decade-plus of live operating history through several biotech cycles.

Worth knowing

  1. 01Thinly traded next to the giants of the category, so spreads and limit orders matter more here than with the household names.
  2. 02Several funds in the same biotech cohort screen stronger overall, and some cost less: IBBQ at 0.19% and XBI at 0.35% versus SBIO's 0.50%.
  3. 03Not an income vehicle. Whatever this fund does, it does through the share prices of the drug developers it holds.

SBIO Holdings

As of Sep 20, 2026, 6:07 AM
Asset class
Stocks
Holdings
103
Top-10 weight
30%
Largest holding
CGON3.9%

Sectors

  • Health Care100.0%

Geography

  • United States89.63%
  • United Kingdom2.29%
  • Canada2.24%
  • China1.68%
  • Netherlands1.57%
  • Belgium1.46%
  • Germany0.75%
  • Switzerland0.36%
The fund’s holdings, weight-ordered — page 1 of 7.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001CGONCG oncology Inc.3.86%116,606$9M94
002ORKAOruka Therapeutics Inc.3.67%87,095$8M89
003TVTXTravere Therapeutics Inc.3.45%123,993$8M109
004DNTHDianthus Therapeutics Inc.3.16%73,582$7M81
005DFTXDefinium Therapeutics Inc.3.04%176,756$7M66
006EWTXEdgewise Therapeutics Inc.2.87%142,864$6M67
007ACADACADIA Pharmaceuticals Inc.2.74%226,658$6M128
008MANEVeraDermics Inc.2.60%54,956$6M56
009RLAYRelay Therapeutics Inc.2.41%288,271$5M93
010AMLXAmylyx Pharmaceuticals Inc.2.37%165,103$5M71
011XENEXenon Pharmaceuticals Inc.2.24%127,389$5M66
012IDYAIdeaya Biosciences Inc.2.16%126,929$5M91
013TARSTarsus Pharmaceuticals Inc.2.00%57,730$5M73
014DYNDyne Therapeutics Inc.1.86%245,653$4M84
015DNLIDenali Therapeutics Inc.1.84%210,272$4M88

Showing 1–15 of 105 holdings

SBIO Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

SBIO$16,880
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. SBIO $16,880. SPY $11,723. Use the arrow keys to read each point.$8,785$14,197$19,609Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for SBIO. Periods over one year show the average yearly return.
PeriodSBIO
Year to date+23.7%
1 month−8.3%
3 months+8.0%
1 year+68.8%
3 years+34.0%per year
5 years+7.1%per year
10 years+9.7%per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for SBIO
YearReturn barSBIO
2026 YTD+23.7%
2025+55.1%
2024+3.8%
2023+8.7%
2022−28.1%
2021−17.5%
2020+21.2%

SBIO in the news

SBIO Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
0.00%Last 12 months
Payout per share
NoneLast 12 months

No distributions in the last 12 months.

Distribution history

Payments through 2024

One bar per payment. 5 payments from 2017 to 2024. Dec 21, 2017 $0.58; Dec 20, 2018 $0.78; Dec 19, 2019 $0.02; Dec 21, 2023 $0.07; Dec 19, 2024 $1.17. Use the arrow keys to read each point.20172018201920202021202220232024
Ex-datePay dateAmount per share
Dec 19, 2024Dec 26, 2024$1.17
Dec 21, 2023Dec 27, 2023$0.07
Dec 19, 2019Dec 27, 2019$0.02
Dec 20, 2018Dec 27, 2018$0.78
Dec 21, 2017Dec 28, 2017$0.58

SBIO Risk

How much the fund’s monthly returns vary, scaled to a year.
28.0%
Annualised · 36 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.99
vs 3-month T-bills · to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−52.5%
Trough Oct 2023
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.95
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

SBIO Cost

Expense ratio0.50%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

8 of the 15 Biotech & Genomics funds charge less.

SBIO costs $50.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.